Immune function modulating agents
US9314041B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 23, 2006 |
| Grant date | Apr 19, 2016 |
| Priority date | — |
| Expiry date | Jan 13, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12R2001/225
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A probiotic lactobacillus was discovered from lactobacilli of the Lactobacillus genus independently isolated from human adult feces. The probiotic lactobacillus was selected from other bacterial strains for: (1) being highly resistant to gastric acid/bile acid; (2) having a high promoting activity on IL-12 production from mouse derived spleen cells and a high Th1/Th2 balance-improving effect; (3) having a high ability to inhibit the production of antigen-specific IgE induced by intraperitoneally administering ovalbumin to BALB/c mice; (4) having a high ability to inhibit the production of antigen-specific IgE induced by orally administering a food antigen to C57BL/6N mice; (5) having a high Natural Killer cell-activating ability; (6) having a high IL-12 production-promoting activity on spleen cells and mesenteric lymph node cells derived from mice immunized with ovalbumin and a high Th1/Th2 balance-improving effect; and (7) having a high ability to suppress eosinophilia induced by a cedar pollen-extracted antigen. This discovery led to the completion of the present invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.